Retatrutide Bali
Frequently Asked Questions About Retatrutide
Answers about how Retatrutide works, what the published evidence shows, and how to check the labelled 32 mg pen in Bali.
Order on WhatsAppAbout the product and the evidence
What is Retatrutide?
Retatrutide is an investigational peptide that activates the receptors for GLP-1, GIP, and glucagon. Researchers are studying its effects on body weight and other metabolic outcomes. In obesity trials it has been compared with placebo under controlled conditions. The 32 mg label on the Body Pharm pen describes a separate catalog item.
How does Retatrutide work?
Retatrutide acts on three hormone receptors. GLP-1 and GIP are involved in the body’s response to eating, and glucagon signals the liver to make glucose available. Preclinical experiments also suggest a role for energy expenditure. Human trials measure the overall response to the molecule. They cannot separate out how much weight change comes from each receptor.
Is Retatrutide a GLP-1 medication?
It has GLP-1 receptor activity. Calling it a triple agonist gives a fuller description because it also activates GIP and glucagon receptors. Single-target GLP-1 medicines and investigational retatrutide have different sets of receptors and different regulatory histories.
What is a triple agonist?
An agonist activates a receptor, a protein that receives a signal in the body. A triple agonist can activate three kinds of receptor. In this case one peptide has activity at the GLP-1, GIP, and glucagon receptors. The term describes its targets. It carries no claim about the size of an individual's response.
How is Retatrutide different from Tirzepatide?
Both activate GIP and GLP-1 receptors. Retatrutide also activates the glucagon receptor and remains investigational. Specific tirzepatide products have approvals for defined indications. The phase 2 retatrutide trial and the 72-week SURMOUNT-1 tirzepatide trial used different participants and designs. TRIUMPH-5 is the registered direct comparison of the two molecules.
What do Retatrutide clinical trials show?
The 2023 phase 2 trial found greater average weight reductions with retatrutide than placebo at both 24 and 48 weeks. A separate phase 3 trial, TRIUMPH-1, reported an average 25.0% reduction in its 12 mg group at week 80 and 3.9% with placebo in the intention-to-treat analysis. Group results depend on the study population and follow-up.
What were the 48-week results?
In the phase 2 trial, estimated mean weight reductions were 8.7% in the 1 mg group, 17.1% in the combined 4 mg group, 22.8% in the combined 8 mg group, and 24.2% in the 12 mg group. Placebo averaged 2.1%. The milligram labels identify study groups. The percentages refer to change from starting body weight.
What are the known side effects?
Digestive symptoms, including nausea, diarrhea, vomiting, and constipation, were reported in the phase 2 trial. Most were mild or moderate and occurred more often in higher-dose groups. The investigators also recorded increases in heart rate. A trial of this size and duration provides limited information about uncommon or long-term adverse effects.
Is Retatrutide FDA-approved?
No. FDA says retatrutide is not an ingredient in any FDA-approved drug. Published studies and a phase 3 development program establish that the molecule is being investigated. They do not authorize commercial pens labeled with its name. The references include FDA’s current notice on unapproved products.
Is Retatrutide available as a prefilled pen?
The Bali catalog pictures a Body Pharm prefilled pen labeled “Retatrutide 32 mg.” Lilly describes its investigational retatrutide as available through its clinical trials. The catalog listing and photographs do not establish that the pen is sponsor-supplied trial medication or authorized for human use.
What does 32 mg mean on the product label?
It is the manufacturer’s stated total amount in the entire pen. The number does not state the amount delivered in a particular injection or how long a pen would last. It is a packaging specification, and it serves a different purpose from the target-group labels used in the research chart.
How can I verify product documentation?
The manufacturer’s certificate shown here identifies lot C-Re32-2.4-20251011. Compare that exact code with the lot on the supplied pack. The report lists separate results for identification, purity, sterility, and bacterial endotoxins. Each result concerns the submitted sample. The certificate cannot authenticate a different lot or establish an Indonesian marketing authorization.
What storage conditions does the manufacturer specify?
For lot C-Re32-2.4-20251011, the Body Pharm certificate specifies a sealed container in a dark place at 2–8°C and says to avoid freezing. Check the instructions and expiry on the supplied pack. The report documents the manufacturer’s storage conditions for the named lot.
What is the regulatory status of Retatrutide in Indonesia?
We could not verify an Indonesian BPOM marketing authorization for the Body Pharm Retatrutide 32 mg pen. Lilly describes its retatrutide as investigational. BPOM’s public medicines database lets readers check the product name, registration holder, presentation, and registration number. A contact or listing in Bali does not establish approval.
Where can I read the original clinical studies?
Jastreboff and colleagues published the 2023 phase 2 trial and the 2026 TRIUMPH-1 trial in the New England Journal of Medicine. Their article records appear in the references below. ClinicalTrials.gov record NCT04881760 describes the phase 2 protocol. For the direct comparison with tirzepatide, consult NCT06662383.
Ask the Bali team
Tell us how many Retatrutide pens you want and where in Bali you are staying. We can confirm availability, the delivered price and a time that works for you.